Latest news

• Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

  hoping to add to its portfolio with new therapies for breast cancer ( abemaciclib) and migraine ( galcanezumab).

• Race to CGRP migraine drug finish line enters the final straight

  US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab. Amgen and partner Novartis are looking at getting an FDA decision on their new CGRP inhibitor drug for migraine by ... The US regulator has accepted the marketing

• Lilly set to head to regulators with CGRP migraine drug

  Lilly set to head to regulators with CGRP migraine drug. Gathers three positive late-stage trials of galcanezumab as it chases Amgen. ... Three positive phase III trials put Eli Lilly on course to file its CGRP inhibitor galcanezumab later this year, as

• Lilly to buy migraine drug developer CoLucid for $960m

  Lilly is already developing a preventative treatment called galcanezumab, a calcitonin gene-related peptide (CGRP) inhibitor which is in phase III testing in migraine and cluster headache and should have first ... This innovation, along with galcanezumab,

• Lilly planning 20 new launches by 2023

  In pain control - which Lilly views as an emerging R&D focus - the company highlighted galcanezumab, potentially a first-in-class CGRP inhibitor for cluster headache and migraine, as well as